Compare · MMM vs NPCE
MMM vs NPCE
Side-by-side comparison of 3M Company (MMM) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $85.26B, about 194.4x NPCE ($438.7M).
- Over the past year, MMM is up 6.4% and NPCE is up 14.0% - NPCE leads by 7.5 points.
- MMM has hit the wire 8 times in the past 4 weeks while NPCE has been quiet.
- MMM has more recent analyst coverage (25 ratings vs 17 for NPCE).
- Company
- 3M Company
- Neuropace Inc.
- Price
- $164.68-0.33%
- $12.25-3.92%
- Market cap
- $85.26B
- $438.7M
- 1M return
- -0.03%
- -13.73%
- 1Y return
- +6.41%
- +13.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 17
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest MMM
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- 13-Year-old Raji Doshi named America's Top Young Scientist for inventing an algae-aragonite alkalinity system to reduce CO2-driven ocean acidification
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 3 filed by 3M Company
- 3M Announces Upcoming Investor Event
- EVP & Chief Financial Officer Maheshwari Anurag exercised 10,944 shares at a strike of $163.02 and covered exercise/tax liability with 4,991 shares, increasing direct ownership by 93% to 12,365 units (SEC Form 4)
- Wells Fargo initiated coverage on 3M with a new price target
- 3M upgraded by Bernstein with a new price target
Latest NPCE
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.65% to 51,357 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Williams Patrick F. covered exercise/tax liability with 1,162 shares, decreasing direct ownership by 2% to 67,508 units (SEC Form 4) (tax liability)
- KeyBanc Capital Markets initiated coverage on NeuroPace with a new price target
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,310 shares, decreasing direct ownership by 0.94% to 138,000 units (SEC Form 4) (for tax liability)
- NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
- NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.80% to 139,310 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.69% to 51,692 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.
- SEC Form 10-Q filed by Neuropace Inc.